UPDATE 1-U.S. FDA places Mersana's cancer drug trial on hold following death

[admin]

Mersana Therapeutics Inc said on Monday the U.S. drug regulator had placed on hold an early-stage trial testing its experimental cancer drug after the death of a participant. The death was of a patient enrolled at the initial dose level in the dose escalation portion, the company said. The company is now focused on analyzing the death and "consider potential next steps for development,” Chief Executive Officer Anna Protopapas said in a statement.